GlassScriptPhysician profile
Paul Deutsch
NPI 1811990013
$25,428.11
in general payments reported to CMS, 2019-2025
91 companies · $3,321 in 2025
The $3,321 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,613 · 2020: $3,358 · 2021: $4,520 · 2022: $3,649 · 2023: $3,037 · 2024: $3,931 · 2025: $3,321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,122.20 |
| Education | $166.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,323.59 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $2,027.61 | 2019-2025 | Breztri, Farxiga, Lokelma |
| Novo Nordisk INC | $1,977.89 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,700.57 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Pfizer INC. | $1,664.15 | 2019-2025 | |
| Astellas Pharma US INC | $1,294.96 | 2019-2025 | Veozah, Myrbetriq |
| Amgen INC. | $1,208.36 | 2019-2025 | Evenity, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $1,022.05 | 2019-2025 | Gardasil 9, Capvaxive, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $975.35 | 2019-2025 | Jardiance, Tradjenta, Ofev |
| Lilly USA, LLC | $700.90 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Allergan, INC. | $619.95 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $583.32 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $577.72 | 2019-2021 | |
| Amarin Pharma, INC. | $544.42 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $525.31 | 2019-2025 | Trintellix |
Show all 91 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Deutsch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.